Lipid management and peripheral arterial disease

被引:17
作者
Daskalopoulou, S. S.
Daskalopoulos, M. E.
Mikhailidis, D. P.
Liapis, C. D.
机构
[1] Univ London Royal Free Hosp, Sch Med, Dept Clin Biochem, London NW3 2QG, England
[2] Univ London Royal Free Hosp, Sch Med, Dept Surg, London NW3 2QG, England
[3] Univ Athens, Sch Med, Dept Vasc Surg, GR-11527 Athens, Greece
[4] McGill Univ, Div Clin Epidemiol, Dept Med, Montreal, PQ, Canada
关键词
peripheral arterial disease; risk factors; dyslipidemia; lipid lowering; statins; prevention;
D O I
10.2174/138945007780362737
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a "cluster" of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target (< 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.
引用
收藏
页码:561 / 570
页数:10
相关论文
共 146 条
[1]
Abramson BL, 2005, CAN J CARDIOL, V21, P997
[2]
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease - A randomized, placebo-controlled study [J].
Alber, HF ;
Frick, M ;
Suessenbacher, A ;
Doerler, J ;
Schirmer, M ;
Stocker, EM ;
Dichtl, W ;
Pachinger, O ;
Weidinger, F .
AMERICAN HEART JOURNAL, 2006, 151 (01) :139.e1-139.e7
[3]
Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease [J].
Alnaeb, ME ;
Youssef, F ;
Mikhailidis, DP ;
Hamilton, G .
ANGIOLOGY, 2006, 57 (01) :65-71
[4]
Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease [J].
Alobaid, N ;
Alnaeb, ME ;
Sales, KM ;
Seifalian, AM ;
Mikhailidis, DP ;
Hamilton, G .
ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2005, 12 (5-6) :243-250
[5]
Ambrosetti M, 2006, INT ANGIOL, V25, P14
[6]
[Anonymous], 2002, JAMA
[7]
Aronow WS, 2003, J GERONTOL A-BIOL, V58, P573
[8]
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥ 125 mg/dl treated with statins versus no lipid-lowering drug [J].
Aronow, WS ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (07) :789-+
[9]
Effect of Simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment [J].
Aronow, WS ;
Nayak, D ;
Woodworth, S ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) :711-712
[10]
Association between plasma homocysteine and peripheral arterial disease in older persons [J].
Aronow, WS ;
Ahn, C .
CORONARY ARTERY DISEASE, 1998, 9 (01) :49-50